prl3-zumab

Cancer

National Cancer Centre, SingaporePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 59/ 100

Competitive context

1411 Active assets in the Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

prl3-zumab is also rated in:

Advanced Solid CancersDormant

B

Indicative ·

57 / 100

Advanced Malignant Solid TumorDormant

CCC

Indicative ·

51 / 100

gastric cancerDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.